GPC1 and glioblastoma: Ghosh et al. evaluated [89Zr]-DFO-Miltuximab and its antibody fragments (Fab′2, Fab, and scFv) as GPC-1 targeting immuno-PET agents for glioblastoma imaging.63 Miltuximab, a clinical-stage chimeric monoclonal antibody developed by GlyTherix Ltd., specifically targets GPC-1.